FDA Grants Second Approval under the National Priority Voucher Pilot Program

26 Feb 20264 min read0 views

GIST

The U.S. Food and Drug Administration today issued an approval for the lung cancer drug Hernexeos (zongertinib) as a part of the new Commissioner's National Priority Voucher (CNPV) pilot program.

Clinical Editorial

Summary

FDA News Releases published a clinical update in Research Highlights on 26 Feb 2026. The item focuses on FDA Grants Second Approval under the National Priority Voucher Pilot Program. Open the detail page to review the full original feed content.